{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:30:47Z","timestamp":1761708647519,"version":"build-2065373602"},"reference-count":71,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.ecl.2011.01.003","type":"journal-article","created":{"date-parts":[[2011,4,15]],"date-time":"2011-04-15T13:27:29Z","timestamp":1302874049000},"page":"265-277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Overview of Endocrine Systems in Primary Hypertension"],"prefix":"10.1016","volume":"40","author":[{"given":"Robert M.","family":"Carey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ecl.2011.01.003_bib1","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.ecl.2011.01.003_bib2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1152\/physrev.1977.57.2.313","article-title":"Renin-angiotensin system: biochemistry and mechanisms of action","volume":"57","author":"Peach","year":"1977","journal-title":"Physiol Rev"},{"key":"10.1016\/j.ecl.2011.01.003_bib3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1210\/er.2003-0001","article-title":"Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular regulation","volume":"24","author":"Carey","year":"2003","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ecl.2011.01.003_bib4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM197203022860901","article-title":"Essential hypertension: renin and aldosterone, heart attack and stroke","volume":"286","author":"Brunner","year":"1972","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2011.01.003_bib5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.1979.03290280031022","article-title":"Renin profiling for diagnosis and treatment of hypertension","volume":"241","author":"Laragh","year":"1979","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2011.01.003_bib6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1161\/01.RES.36.6.2","article-title":"Evidence for a new mineralocorticoid in patients with low-renin essential hypertension","volume":"36","author":"Sennett","year":"1975","journal-title":"Circ Res"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2011.01.003_bib7","first-page":"99","article-title":"Renin subgroups in essential hypertension. Further analysis of their pathophysiological and epidemiological characteristics","volume":"32","author":"Brunner","year":"1973","journal-title":"Circ Res"},{"key":"10.1016\/j.ecl.2011.01.003_bib8","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1210\/jcem-49-5-790","article-title":"Low renin essential hypertension: failure to demonstrate excess 11-deoxycorticosterone production","volume":"49","author":"Tan","year":"1979","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2011.01.003_bib9","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM199104183241605","article-title":"Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension","volume":"324","author":"Alderman","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2011.01.003_bib10","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJM199308263290905","article-title":"Plasma renin activity and ischemic heart disease","volume":"329","author":"Meade","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2011.01.003_bib11","series-title":"Hypertension: pathophysiology, diagnosis and management","first-page":"1837","article-title":"Abnormal renal function, sodium-volume homeostasis and renin system behavior in normal-renin essential hypertension: the evaluation of the non-modulator concept","author":"Hollenberg","year":"1995"},{"key":"10.1016\/j.ecl.2011.01.003_bib12","doi-asserted-by":"crossref","first-page":"3A","DOI":"10.1016\/S0002-9149(01)02321-9","article-title":"The role of the renin-angiotensin system in the development of cardiovascular disease","volume":"89","author":"Unger","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ecl.2011.01.003_bib13","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/01.hjh.0000165623.72310.dd","article-title":"The cardiovascular continuum and renin-angiotensin-aldosterone system blockade","volume":"23","author":"Dzau","year":"2005","journal-title":"J\u00a0Hypertens Suppl"},{"key":"10.1016\/j.ecl.2011.01.003_bib14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1524-6175.2003.02836.x","article-title":"Combination angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy: its role in clinical practice","volume":"5","author":"Sica","year":"2003","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.ecl.2011.01.003_bib15","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2011.01.003_bib16","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2011.01.003_bib17","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2011.01.003_bib18","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2011.01.003_bib19","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","article-title":"Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial","volume":"353","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2011.01.003_bib20","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1097\/00004872-200307006-00007","article-title":"The telmisartan programme of research tO show Telmisartan End-organ proteCTION (PROTECTION) programme","volume":"21","author":"Weber","year":"2003","journal-title":"J\u00a0Hypertens Suppl"},{"key":"10.1016\/j.ecl.2011.01.003_bib21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11906-003-0073-2","article-title":"The role of angiotensin II in regulating vascular structural and functional changes in hypertension","volume":"5","author":"Touyz","year":"2003","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.ecl.2011.01.003_bib22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00041552-200503000-00007","article-title":"Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II","volume":"14","author":"Touyz","year":"2005","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.ecl.2011.01.003_bib23","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1152\/physrev.2001.81.3.999","article-title":"Vascular smooth muscle growth: autocrine growth mechanisms","volume":"81","author":"Berk","year":"2001","journal-title":"Physiol Rev"},{"key":"10.1016\/j.ecl.2011.01.003_bib24","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1357-2725(02)00271-6","article-title":"Inflammation and angiotensin II","volume":"35","author":"Suzuki","year":"2003","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.ecl.2011.01.003_bib25","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1210\/jc.2002-021836","article-title":"Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action","volume":"88","author":"Dandona","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2011.01.003_bib26","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1161\/01.HYP.0000100443.09293.4F","article-title":"Reactive oxygen species in the vasculature: molecular and cellular mechanisms","volume":"42","author":"Taniyama","year":"2003","journal-title":"Hypertension"},{"issue":"Suppl 12","key":"10.1016\/j.ecl.2011.01.003_bib27","first-page":"S258","article-title":"Angiotensin II and long-term arterial pressure regulation: the overriding dominance of the kidney","volume":"10","author":"Hall","year":"1999","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ecl.2011.01.003_bib28","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1161\/01.CIR.101.14.1653","article-title":"Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan","volume":"101","author":"Schiffrin","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ecl.2011.01.003_bib29","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1172\/JCI23378","article-title":"Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system","volume":"115","author":"Crowley","year":"2005","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ecl.2011.01.003_bib30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/01.CIR.98.1.73","article-title":"Angiotensin production by the heart: a quantitative study in pigs with the use of radiolabeled angiotensin infusions","volume":"98","author":"van Kats","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ecl.2011.01.003_bib31","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1046\/j.1523-1755.2001.00049.x","article-title":"Intrarenal angiotensin II: interstitial and cellular levels and site of production","volume":"60","author":"van Kats","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.ecl.2011.01.003_bib32","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1161\/01.CIR.102.13.1556","article-title":"Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II","volume":"102","author":"van Kats","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ecl.2011.01.003_bib33","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s11906-005-0086-0","article-title":"Is angiotensin II made inside or outside of the cell?","volume":"7","author":"Chai","year":"2005","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.ecl.2011.01.003_bib34","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0025-7125(03)00124-X","article-title":"Tissue renin angiotensin systems","volume":"88","author":"Re","year":"2004","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.ecl.2011.01.003_bib35","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1161\/01.RES.40.2.174","article-title":"Effect of intrarenal angiotensin II blockade on renal function in conscious dogs","volume":"40","author":"Kimbrough","year":"1977","journal-title":"Circ Res"},{"key":"10.1016\/j.ecl.2011.01.003_bib36","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1210\/endo-112-1-43","article-title":"Control of renal function by intrarenal angiotensin II","volume":"112","author":"Levens","year":"1983","journal-title":"Endocrinology"},{"key":"10.1016\/j.ecl.2011.01.003_bib37","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1161\/hy0202.103821","article-title":"Regulation of intrarenal angiotensin II in hypertension","volume":"39","author":"Navar","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.ecl.2011.01.003_bib38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11906-003-0070-5","article-title":"Intrarenal angiotensin II and hypertension","volume":"5","author":"Navar","year":"2003","journal-title":"Curr Hypertens Rep"},{"issue":"11","key":"10.1016\/j.ecl.2011.01.003_bib39","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1681\/ASN.2006040356","article-title":"Renin-angiotensin-aldosterone system and progression of renal disease","volume":"17","author":"R\u00fcster","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ecl.2011.01.003_bib40","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1161\/01.HYP.37.5.1329","article-title":"Enhancement of angiotensinogen expression in angiotensin II-dependent hypertension","volume":"37","author":"Kobori","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.ecl.2011.01.003_bib41","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1161\/01.HYP.34.6.1265","article-title":"Elements of a paracrine tubular renin-angiotensin system along the entire nephron","volume":"34","author":"Rohrwasser","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.ecl.2011.01.003_bib42","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/01.HYP.0000050102.90932.CF","article-title":"Urinary angiotensinogen as an indicator of intrarenal angiotensin status in hypertension","volume":"41","author":"Kobori","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.ecl.2011.01.003_bib43","doi-asserted-by":"crossref","first-page":"F632","DOI":"10.1152\/ajprenal.00462.2004","article-title":"AT1 receptor-mediated enhancement of collecting duct renin in angiotensin II-dependent hypertensive rats","volume":"289","author":"Prieto-Carrasquero","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.ecl.2011.01.003_bib44","doi-asserted-by":"crossref","first-page":"F965","DOI":"10.1152\/ajprenal.00402.2003","article-title":"Increased blood pressure in transgenic mice expressing both human renin and angiotensinogen in the renal proximal tubule","volume":"286","author":"Lavoie","year":"2004","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.ecl.2011.01.003_bib45","doi-asserted-by":"crossref","first-page":"17985","DOI":"10.1073\/pnas.0605545103","article-title":"Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney","volume":"103","author":"Crowley","year":"2006","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.ecl.2011.01.003_bib46","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.tem.2005.02.010","article-title":"Aldosterone as a cardiovascular risk factor","volume":"16","author":"Rossi","year":"2005","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.ecl.2011.01.003_bib47","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1210\/jc.2008-0104","article-title":"Case detection, diagnosis and treatment of patients with primary aldosteronism. A Clinical Practice Guideline of The Endocrine Society","volume":"93","author":"Funder","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2011.01.003_bib48","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00004872-199205000-00011","article-title":"Abnormalities of glucocorticoid metabolism and the renin-angiotensin system: a four-corners approach to the identification of genetic determinants of blood pressure","volume":"10","author":"Watt","year":"1992","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.ecl.2011.01.003_bib49","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.1210\/en.2006-0826","article-title":"Minireview: aldosterone and the cardiovascular system: genomic and nongenomic effects","volume":"147","author":"Funder","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.ecl.2011.01.003_bib50","doi-asserted-by":"crossref","first-page":"4796","DOI":"10.1210\/en.2004-0295","article-title":"Origin of aldosterone in the rat heart","volume":"145","author":"Gomez-Sanchez","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.ecl.2011.01.003_bib51","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1210\/en.2004-1057","article-title":"Cardiac synthesis of aldosterone: going, going, gone\u2026?","volume":"145","author":"Funder","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.ecl.2011.01.003_bib52","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/cvr\/26.7.671","article-title":"Reactive and reparative myocardial fibrosis in arterial hypertension in the rat","volume":"26","author":"Brilla","year":"1992","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ecl.2011.01.003_bib53","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1006\/jmcc.1993.1066","article-title":"Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism","volume":"25","author":"Brilla","year":"1993","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.ecl.2011.01.003_bib54","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","article-title":"Aldosterone: a mediator of myocardial necrosis and renal arteriopathy","volume":"141","author":"Rocha","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.ecl.2011.01.003_bib55","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1056\/NEJMp048132","article-title":"Aldosterone\u2013villain or bystander?","volume":"351","author":"Dluhy","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2011.01.003_bib56","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","article-title":"Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats","volume":"33","author":"Rocha","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.ecl.2011.01.003_bib57","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","article-title":"Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats","volume":"31","author":"Rocha","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.ecl.2011.01.003_bib58","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10741-005-2346-0","article-title":"Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation","volume":"10","author":"Joffe","year":"2005","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ecl.2011.01.003_bib59","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.tem.2005.02.004","article-title":"Low renin hypertensive states: perspectives, unsolved problems, future research","volume":"16","author":"Gordon","year":"2005","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.ecl.2011.01.003_bib60","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa033263","article-title":"Serum aldosterone and the incidence of hypertension in nonhypertensive persons","volume":"351","author":"Vasan","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2011.01.003_bib61","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1152\/physrev.1990.70.4.963","article-title":"Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions","volume":"70","author":"Esler","year":"1990","journal-title":"Physiol Rev"},{"key":"10.1016\/j.ecl.2011.01.003_bib62","doi-asserted-by":"crossref","first-page":"H1895","DOI":"10.1152\/ajpheart.00486.2004","article-title":"Collateral damage: cardiovascular consequences of chronic sympathetic activation with human aging","volume":"287","author":"Seals","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ecl.2011.01.003_bib63","doi-asserted-by":"crossref","first-page":"R909","DOI":"10.1152\/ajpregu.00335.2001","article-title":"The influence of aging on the human sympathetic nervous system and brain norepinephrine turnover","volume":"282","author":"Esler","year":"2002","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.ecl.2011.01.003_bib64","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/00004872-200103001-00001","article-title":"Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why)","volume":"19","author":"Landsberg","year":"2001","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.ecl.2011.01.003_bib65","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1152\/japplphysiol.00557.2001","article-title":"Noradrenergic content and turnover rate in kidney and heart shows gender and strain differences","volume":"92","author":"Caplea","year":"2002","journal-title":"J\u00a0Appl Physiol"},{"key":"10.1016\/j.ecl.2011.01.003_bib66","doi-asserted-by":"crossref","first-page":"R441","DOI":"10.1152\/ajpregu.00669.2001","article-title":"Sympathetic-renal interaction in chronic arterial pressure control","volume":"283","author":"Grisk","year":"2002","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.ecl.2011.01.003_bib67","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.cardiores.2003.11.024","article-title":"Interactions between the sympathetic nervous system and the kidneys in arterial hypertension","volume":"61","author":"Grisk","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ecl.2011.01.003_bib68","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/hy0202.103471","article-title":"Sympathetic activation in adipose tissue and skeletal muscle of hypertensive rats","volume":"39","author":"Cabassi","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.ecl.2011.01.003_bib69","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1161\/01.HYP.36.5.824","article-title":"Phenotypic evidence of faulty neuronal norepinephrine reuptake in essential hypertension","volume":"36","author":"Rumantir","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.ecl.2011.01.003_bib70","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/00004872-199917080-00012","article-title":"Neural mechanisms in human obesity-related hypertension","volume":"17","author":"Rumantir","year":"1999","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.ecl.2011.01.003_bib71","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1161\/01.HYP.11.1.3","article-title":"Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover","volume":"11","author":"Esler","year":"1988","journal-title":"Hypertension"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852911000041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852911000041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:33:33Z","timestamp":1760175213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852911000041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0889852911000041"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2011.01.003","relation":{},"ISSN":["0889-8529"],"issn-type":[{"type":"print","value":"0889-8529"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overview of Endocrine Systems in Primary Hypertension","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2011.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}